Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13820 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Jan Bosák und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zentiva, k.s., Prague, Czech Republic. Hauptthemen laut MEDLINE: Rivaroxaban, Cross-Over Studies, Biological Availability, Food-Drug Interactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The bioavailability of rivaroxaban at the higher doses (15 and 20 mg) is considerably reduced when the drug is administered on an empty stomach. This can lead to inadequate anticoagulant effect, and therefore, it is recommended to use the higher doses at fed state. However, proper posology may represent a barrier for some patients. Therefore, the aim of this study was to evaluate innovative rivaroxaban‐containing formulations designed to eliminate the food effect to ensure reliable absorption and thus to improve patient adherence with the treatment. Three prototypes (Cocrystal, HPMCP and Kollidon) with rivaroxaban were developed and their bioavailability and food effect in comparison to the reference product was tested in open label, randomized, single oral dose, crossover studies, where test products were administered under fasting and fed conditions and the reference product was administered under fed conditions. Comparable bioavailability for all tested prototypes both under fed and fasting conditions was demonstrated as the 90% confidence intervals of the geometric mean ratios for area under the concentration–time curve remained within the standard acceptance range of 80.00%–125.00%. An innovative immediate release form of rivaroxaban with no food effect on drug bioavailability has been developed, which may represent an important step toward increasing adherence, improving treatment outcome and reducing health care costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zentiva, k.s., Prague, Czech Republic.
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic.
ORCID-Profile: Martin Šíma, Jaroslava Šmardová, Tomáš Křížek, Ondřej Slanař
Zitieren
APA
Bosák, J., Šíma, M., Krejčí, T., Obadalová, I., Šmardová, J., Kozlík, P., Křížek, T., Beránek, J., Hauser, T., & Slanař, O. (2024). Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes. Clinical and Translational Science. https://doi.org/10.1111/cts.13820
Vancouver
Bosák J, Šíma M, Krejčí T, Obadalová I, Šmardová J, Kozlík P, et al. Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes. Clinical and Translational Science. 2024. doi:10.1111/cts.13820
BibTeX
@article{Bosk2024,
author = {Bosák, Jan and Šíma, Martin and Krejčí, Tereza and Obadalová, Iva and Šmardová, Jaroslava and Kozlík, Petr and Křížek, Tomáš and Beránek, Josef and Hauser, Tomáš and Slanař, Ondřej},
title = {Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13820}
}
EUVIMED